Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) Shares Outstanding (Diluted Average) (2016 - 2025)

Jaguar Health (JAGX) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 691.9% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 691.9% year-over-year, with the annual reading at $2.3 million for FY2025, 691.9% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $2.3 million at Jaguar Health, up from $1.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $45.8 million in Q3 2021, with the low at $15421.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $7.7 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 98.82% in 2023, then soared 1809.95% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $596154.0 in 2021, then surged by 120.0% to $1.3 million in 2022, then plummeted by 98.82% to $15421.0 in 2023, then skyrocketed by 1809.95% to $294534.0 in 2024, then surged by 691.9% to $2.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $2.3 million, $1.3 million, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.